NEW YORK (GenomeWeb News) – BGI Health and partners in Turkey have inked a memorandum of understanding to bring genetic testing technologies, including non-invasive fetal trisomy testing, to that country, BGI Health announced this week.
The deal is between BGI Health — a commercial arm of BGI — and Turkish healthcare services provider Acibadem Healthcare Group Genetic Diagnostic Center in cooperation with Turkish firm Genoks Company Molecular Biology. According to BGI Health, the partnership will conduct genetic testing of monogenic disorders, exome sequencing-based personalized medicine, non-invasive fetal trisomy testing, and HLA genotyping, among other testing efforts.
Financial and other terms of the deal were not disclosed.
Ning Li, director of BGI-Europe, said in a statement that the collaboration will "advance the clinical applications of genetic testing technologies and develop better solutions to address the challenges of hereditary diseases."